CPI-0610, A bromodomain and extraterminal domain (bet) protein inhibitor, in combination with ruxolitinib, in jak inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Authors
Palandri, F.Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Rampal, R.
Vannucchi, A.
Passamonti, F.
Mead, A.
Kremyanskaya, M.
Somervaille, Tim C P
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V
Affiliation
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di EmatologiaIssue Date
2021